AVAH vs. CHE: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Aveanna Healthcare (AVAH) or Chemed (CHE). But which of these two stocks is more attractive to value investors?
Aveanna Healthcare: Q1 Results Confirm My Reasons For Optimism
Aveanna Healthcare Holdings reported strong Q1 2026 results, with EPS and revenue significantly beating expectations and shares rising 14% post-earnings. Q1 2026 was the ninth straight quarter in which AVAH has beaten analysts' earnings expectations and the 14th in which it has topped revenue estimates. Key risks include high debt levels, negative free cash flow in Q1 2026, and insider selling, but AVAH's forward PE of 11.4 and PEG ratio of 0.77 support continued upside.
Aveanna Healthcare Holdings Inc. (AVAH) Q1 2026 Earnings Call Transcript
Aveanna Healthcare Holdings Inc. (AVAH) Q1 2026 Earnings Call Transcript
Aveanna Healthcare Q1 Earnings Call Highlights
Aveanna Healthcare NASDAQ: AVAH raised its full-year 2026 outlook after reporting double-digit revenue and adjusted EBITDA growth in the first quarter, citing improved reimbursement rates, higher volumes and operating efficiencies across its three business segments.
Aveanna Healthcare (AVAH) Tops Q1 Earnings and Revenue Estimates
Aveanna Healthcare (AVAH) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.1 per share a year ago.
Unlocking Q1 Potential of Aveanna (AVAH): Exploring Wall Street Estimates for Key Metrics
Evaluate the expected performance of Aveanna (AVAH) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Should Value Investors Buy Aveanna Healthcare (AVAH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
How Much Upside is Left in Aveanna (AVAH)? Wall Street Analysts Think 43.07%
The mean of analysts' price targets for Aveanna (AVAH) points to a 43.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Aveanna Healthcare Holdings: Recent Results Have Me More Optimistic (Rating Upgrade)
Aveanna Healthcare Holdings (AVAH) is upgraded to Buy, reflecting improved profitability and resilient demand for home healthcare services. AVAH's Q4 2025 net income surged, but adjusted EPS was $0.17 due to one-time tax benefits and merger costs. FY 2026 revenue guidance of $2.54–$2.56 billion disappointed, while adjusted EBITDA guidance slightly exceeded consensus.
Aveanna Healthcare Holdings Inc. (AVAH) Q4 2025 Earnings Call Transcript
Aveanna Healthcare Holdings Inc. (AVAH) Q4 2025 Earnings Call Transcript
Aveanna (AVAH) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Aveanna (AVAH) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Aveanna Healthcare (AVAH) Beats Q4 Earnings and Revenue Estimates
Aveanna Healthcare (AVAH) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.05 per share a year ago.
